EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non-motor outcomes and divergent plasma metabolite changes during continuous subcutaneous foslevodopa/foscarbidopa infusion in Parkinson's disease

Kota Igari, Motoki Fujimaki, Masataka Fujimoto, Naoko Kaga, Hikari Taka, Yoshiki Miura, Takashi Hosaka, Ayako Shioya, Makoto Terada, Shinji Saiki

Clinical Parkinsonism & Related Disorders · 2026 · 15 · 100527

DOI: 10.1016/j.prdoa.2026.100527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2026. Verfasst von Kota Igari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Smoking Research Foundation, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating levodopa and metabolite changes during transition to continuous subcutaneous foslevodopa/foscarbidopa infusion (CSCI), and their relationships with clinical outcomes, remain incompletely characterized.

Methods

In this exploratory prospective observational study, 19 patients with advanced Parkinson's disease underwent clinical assessments and fasting morning plasma sampling before CSCI and after clinically judged dose stabilization. Concentration-outcome associations were examined in exploratory post hoc analyses.

Results

At a mean of 16.2 days, median Movement Disorder Society Non-Motor Rating Scale total and gastrointestinal scores decreased from 96 to 80 and 5 to 2 (adjusted P = 0.036 and 0.005); quality of life improved. Mean levodopa and 3-O-methyldopa increased 2.8-fold and 3.2-fold (both adjusted P < 0.001), whereas median free dopamine and 3,4-dihydroxyphenylacetic acid decreased from 10.1 to 5.2 and 575 to 248 nM (adjusted P = 0.003 and 0.021). The exploratory pretreatment dopamine coefficient in the baseline-score-adjusted non-motor model was -3.06 points/nM (95% confidence interval, -6.13 to 0.01; P = 0.051). Larger dopamine reductions were associated with lower baseline-adjusted on-treatment gastrointestinal scores, with attenuation in the catechol-O-methyltransferase (COMT)-related sensitivity cohort. Heteroskedasticity-robust confidence intervals for both dopamine coefficients included zero.

Conclusions

These findings describe concentration changes during transition to a CSCI-based regimen. Dopamine-clinical associations were exploratory; predictive utility and causal mediation were not established.Registration: UMIN000054567, registered 4 June 2024 (retrospectively).

Schlagwörter

Stichwörter der Autor:innen

DopamineFoslevodopa/foscarbidopaGastrointestinal symptomsLevodopaNon-motor symptomsParkinson's disease

Autor:innen und Institutionen

  • Department of Neurology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
  • Jihatsu Research Unit, Tsukuba Institute for Advanced Research (TIAR), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan.
  • Center for Medical Education and Training, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan.
  • Laboratory of Proteomics and Biomolecular Science, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Förderung

  • Smoking Research Foundation
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Igari, K., Fujimaki, M., Fujimoto, M., Kaga, N., Taka, H., Miura, Y., Hosaka, T., Shioya, A., Terada, M., & Saiki, S. (2026). Non-motor outcomes and divergent plasma metabolite changes during continuous subcutaneous foslevodopa/foscarbidopa infusion in Parkinson's disease. Clinical Parkinsonism & Related Disorders, 15, 100527. https://doi.org/10.1016/j.prdoa.2026.100527

Vancouver

Igari K, Fujimaki M, Fujimoto M, Kaga N, Taka H, Miura Y, et al. Non-motor outcomes and divergent plasma metabolite changes during continuous subcutaneous foslevodopa/foscarbidopa infusion in Parkinson's disease. Clinical Parkinsonism & Related Disorders. 2026;15:100527. doi:10.1016/j.prdoa.2026.100527

BibTeX
@article{Igari2026,
  author = {Igari, Kota and Fujimaki, Motoki and Fujimoto, Masataka and Kaga, Naoko and Taka, Hikari and Miura, Yoshiki and Hosaka, Takashi and Shioya, Ayako and Terada, Makoto and Saiki, Shinji},
  title = {Non-motor outcomes and divergent plasma metabolite changes during continuous subcutaneous foslevodopa/foscarbidopa infusion in Parkinson's disease},
  journal = {Clinical Parkinsonism & Related Disorders},
  year = {2026},
  volume = {15},
  pages = {100527},
  doi = {10.1016/j.prdoa.2026.100527}
}
Kostenlos starten →